NCT05388006 2026-03-25Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaMayo ClinicPhase 2 Recruiting27 enrolled
NCT05943496 2025-11-06Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaOHSU Knight Cancer InstitutePhase 1 Recruiting27 enrolled